Spiber Technologies AB

www.spiber.se

Spiber Technologies is a company using recombinant technology for producing advanced biomaterials We develop, produce and market Spiber - a biomaterial made of recombinant spider silk protein. Spiber-based products will become building blocks for culturing stem cells and creating future Regenerative Medicine applications.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical, Industry Outlook

REPLIMUNE AND INCYTE ENTER INTO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT TO EVALUATE RP1 AND INCB99280 IN PATIENTS

Businesswire | August 02, 2023

news image

Replimune Group, Inc. a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor. “We are excited to enter into this collaboration with Incyte to explo...

Read More

Cell and Gene Therapy

RAPID RESHORE & DEVELOPMENT AND BRAINSTORM CELL THERAPEUTICS ANNOUNCE AGREEMENT TO ADVANCE CONSTRUCTION OF BRAINSTORM'S U.S. MANUFACTURING FACILIT

BrainStorm Cell Therapeutics | October 26, 2020

news image

Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner to expedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn® (autologous MSC-NTF) in the U.S. BrainStorm is investigating NurOwn as a potential treatment for neurodegener...

Read More

Medical

RATIO THERAPEUTICS LAUNCHES TO DISCOVER AND DRIVE EARLY CLINICAL DEVELOPMENT OF BEST-IN-CLASS TARGETED RADIOPHARMACEUTICALS FOR TREATMENT OF CANCERS

Ratio Therapeutics | June 13, 2022

news image

Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers. Founded by entrepreneurial scientists Jack Hoppin, Ph.D., and John Babich, Ph.D., Ratio emerges from stealth mode with more than $20 million in seed funding, fully funded development alliances with Bayer AG and Lantheus Holdings Inc., a robust portfolio of assets developed with two proprietary technologies, and a growing team of world-class expert...

Read More

Industrial Impact

SARTORIUS STEDIM BIOTECH TO ACQUIRE ALBUMEDIX, STRENGTHENING ITS PORTFOLIO OF INNOVATIVE ADVANCED THERAPY SOLUTIONS

Sartorius Stedim Biotech | August 09, 2022

news image

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapi...

Read More
news image

Medical, Industry Outlook

REPLIMUNE AND INCYTE ENTER INTO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT TO EVALUATE RP1 AND INCB99280 IN PATIENTS

Businesswire | August 02, 2023

Replimune Group, Inc. a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor. “We are excited to enter into this collaboration with Incyte to explo...

Read More
news image

Cell and Gene Therapy

RAPID RESHORE & DEVELOPMENT AND BRAINSTORM CELL THERAPEUTICS ANNOUNCE AGREEMENT TO ADVANCE CONSTRUCTION OF BRAINSTORM'S U.S. MANUFACTURING FACILIT

BrainStorm Cell Therapeutics | October 26, 2020

Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner to expedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn® (autologous MSC-NTF) in the U.S. BrainStorm is investigating NurOwn as a potential treatment for neurodegener...

Read More
news image

Medical

RATIO THERAPEUTICS LAUNCHES TO DISCOVER AND DRIVE EARLY CLINICAL DEVELOPMENT OF BEST-IN-CLASS TARGETED RADIOPHARMACEUTICALS FOR TREATMENT OF CANCERS

Ratio Therapeutics | June 13, 2022

Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers. Founded by entrepreneurial scientists Jack Hoppin, Ph.D., and John Babich, Ph.D., Ratio emerges from stealth mode with more than $20 million in seed funding, fully funded development alliances with Bayer AG and Lantheus Holdings Inc., a robust portfolio of assets developed with two proprietary technologies, and a growing team of world-class expert...

Read More
news image

Industrial Impact

SARTORIUS STEDIM BIOTECH TO ACQUIRE ALBUMEDIX, STRENGTHENING ITS PORTFOLIO OF INNOVATIVE ADVANCED THERAPY SOLUTIONS

Sartorius Stedim Biotech | August 09, 2022

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapi...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us